The Antifolate Activity of Tea Catechins

Enma Navarro-Perán,¹ Juan Cabezas-Herrera,² Francisco García-Cánovas,¹ Marcus C. Durrant,³ Roger N.F. Thorneley,¹ and José Neptuno Rodríguez-López¹

¹Grupo de Investigación de Enzimología, Departamento de Bioquímica y Biología Molecular A, Facultad de Biología, Universidad de Murcia; ²Servicio de Análisis Clínicos, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; and ³Computational Biology Group and Department of Biological Chemistry, John Innes Centre, Norwich, United Kingdom

Abstract

A naturally occurring gallated polyphenol isolated from green tea leaves, (−)-epigallocatechin gallate (EGCG), has been shown to be an inhibitor of dihydrofolate reductase (DHFR) activity in vitro at concentrations found in the serum and tissues of green tea drinkers (0.1–1.0 μmol/L). These data provide the first evidence that the prophylactic effect of green tea drinking on certain forms of cancer, suggested by epidemiological studies, is due to the inhibition of DHFR by EGCG and could also explain why tea extracts have been traditionally used in “alternative medicine” as antitumorogenic/antibiotic agents or in the treatment of conditions such as psoriasis. EGCG exhibited kinetics characteristic of a slow, tight-binding inhibitor of 7,8-dihydrofolate reduction with bovine liver DHFR (Kᵢ = 0.109 μmol/L), but of a classic, reversible, competitive inhibitor with chicken liver DHFR (Kᵢ = 10.3 μmol/L). Structural modeling showed that EGCG can bind to human DHFR at the same site and in a similar orientation to that observed for some structurally characterized DHFR inhibitor complexes. The responses of lymphoma cells to EGCG and known antifolates were similar, that is, a dose-dependent inhibition of cell growth (IC₅₀ = 20 μmol/L for EGCG), G₀-G₁ phase arrest of the cell cycle, and induction of apoptosis. Folate depletion increased the sensitivity of these cells to antifolates and EGCG. These effects were attenuated by growing the cells in a medium containing hypoxanthine-thymidine, consistent with DHFR being the site of action for EGCG. (Cancer Res 2005; 65(6): 2059-64)

Introduction

Green tea catechins that include (−)-epigallocatechin gallate (EGCG), (−)-epigallocatechin (EGC), (−)-epicatechin gallate (ECG), and (−)-epicatechin (EC) exhibit a range of biological activities (1–3). EGCG has been the most extensively studied because of its pronounced “antifolate activity” by studying in vitro the inhibition of DHFR isolated from two sources, bovine and chicken livers. We have also used the published X-ray structure of human DHFR bound to a tetrahydroquinazoline inhibitor, (R)-6-[(methyl-(3,4,5-trimethoxyphenyl)amino][methyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine (TQD; Fig. 1) to model the binding of EGCG in a manner that can explain the observed tight binding and competitive inhibition with respect to DHF.

Materials and Methods

Dihydrofolate Reductase Assay and Kinetic Data Analysis. Activity measurements for DHFR isolated from chicken liver (Sigma, Madrid, Spain) and bovine liver (Fluka, Madrid, Spain) were made by following the decrease of NADPH (Sigma) and DHF (Sigma) absorbance at 340 nm (Δε = 11,800 mol L⁻¹ cm⁻¹) using a Perkin-Elmer Lambda-2 spectrophotometer thermostatted at 25°C with 1.0-cm path-length cuvettes. Experiments were done in a buffer containing MES (0.025 mol/L), sodium acetate (0.025 mol/L), Tris (0.05 mol/L), and NaCl (0.1 mol/L). To prevent the oxidation of catechins (EGCG, EGC, ECG, and EC purchased from Sigma) the reaction mixture contained 1 mmol/L ascorbic acid (Scharlau, Barcelona, Spain). Initial velocity inhibition experiments were done at a constant and saturating concentration of NADPH (100 μmol/L), whereas concentrations of DHF and the inhibitors (catechins) varied from 0 to 20 μmol/L and from 0 to 100 μmol/L, respectively.
The action of folate analogues, which act as slow-binding inhibitors (I) on DHFR (E), can be described by the following mechanism:

\[ E \overset{k_1}{\underset{k_2}{\rightleftharpoons}} EI \overset{k_3}{\underset{k_4}{\rightleftharpoons}} EI' \]  

(A)

Although the DHFR-catalyzed reaction has been shown to occur via a random mechanism (7), it can be simplified to an ordered mechanism whenever [NADPH] \( > [DHF] \). If the concentration of free inhibitor is not substantially altered by the formation of an enzyme-NADPH inhibitor complex, the progress curve for the inhibition in the presence of saturating NADPH can be described by Eq. B:

\[ P = v_s t + \left( v_0 - v_s \right) \left( 1 - \exp(-k't) \right) / k' \]  

(B)

where \( v_s \), \( v_0 \), and \( k' \) represent the steady-state velocity, initial velocity, and apparent first-order rate constant, respectively. The apparent first-order rate constant is related to the inhibitor concentration by Eq. C, where \( K_m^{DHF} \) is the Michaelis constant of DHFR for DHF:

\[ k' = k_4 \frac{1 + k_1 \frac{[I]}{K_I}}{1 + k_1 \frac{[I]}{K_{I*}} + k_1 \frac{[DHF]}{K_{DHF_m}}} \]  

(C)

\( K_I \) and \( K_{I*} \) denote the respective dissociation constants for the initial and equilibrium binding of inhibitors to the enzyme-NADPH complex. The slow development of catechin inhibition was determined by continuously monitoring the disappearance of NADPH and DHF after initiation of the reaction by the addition of DHFR (3.3 nmol/L). Reaction mixtures contained buffer mixture, NADPH (100 \( \mu \)mol/L), DHF (20 \( \mu \)mol/L), and various concentrations of catechins from 0 to 20 \( \mu \)mol/L. Experiments to determine the maximum steady-state rate (\( v_s \)) and \( K_m^{DHF} \) at several pH values required the analysis of the curvature evident in the time courses for the disappearance of NADPH and DHF (10 determinations). The initial concentration of saturating NADPH (200 \( \mu \)mol/L) was considered to be constant over the period required for the consumption of 10 \( \mu \)mol/L DHF after the addition of DHFR (6 nmol/L). Data were fitted by nonlinear regression to the integrated form of the Michaelis equation (8). The extent of recovery of enzymatic activity after inhibition induced by preincubation with catechins was determined as follows. DHFR (165 nmol/L) was preincubated for 30 minutes at 25°C in the buffer mixture (pH 8.02)
EGCG Inhibits Dihydrofolate Reductase

containing catechin (20 to 50 μmol/L) and ascorbic acid (1 mmol/L). An aliquot of the incubation mixture was then diluted 500-fold into a reaction mixture containing buffer mixture (pH 8.2), NADPH (100 μmol/L), and DHF (20 μmol/L) to give a final enzyme concentration of 0.33 nmol/L. Recovery of enzyme activity was followed by continuous monitoring at 340 nm.

In silico Molecular Modeling of the Interaction between EGCG and Dihydrofolate Reductase. Molecular modeling was done using the Discover module of Insight II (release 2000.1, Accelrys Ltd., Cambridge, United Kingdom). Human DHFR X-ray crystal structure 1SSV (9) was retrieved from the protein data bank (10), and its TQD ligand was used as a template for positioning of the EGCG ligand. The composite protein/EGCG model was geometry optimized within Insight II using the consistent valence force field and steepest descent algorithm to a derivative of 1.0. The refined model was validated within InsightII using Proostat.

Cell Culture Experiments. The mouse lymphoma cell line L1210 was maintained at 37°C in a humid 7.5% CO2/95% air environment for all the experiments. To determine the dose-dependent changes, L1210 cells were plated at a density of 10,000 cells/mL in 96-well plates with a “standard folate” medium [RPMI 1640 supplemented with 10% FCS, 2 mmol/L glutamine, and 100 μg/mL of penicillin and streptomycin (all from Life Technologies, Inc., Barcelona, Spain)] and treated during 4 days with different EGCG concentrations. Cell injury was evaluated by a colorimetric assay for mitochondrial function using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (11). IC50 value was defined as the concentrations that gave a 50% decrease in cellular growth.

Results and Discussion

Inhibition of Dihydrofolate Reductase by Tea Catechins. Steady-state kinetic data showing the inhibition by EGCG of DHF reduction with chicken liver DHFR are shown in Fig. 2A. A Kι (10.3 μmol/L) for EGCG as a competitive inhibitor of DHF calculated from the secondary plot (Fig. 2B) is compared in Table 1 with values for methotrexate (1.3 mmol/L) and trimethoprim (3.5 μmol/L). Preincubation of the enzyme with EGCG did not produce any measurable inhibition. Thus, the inhibition shown in Fig. 2A and B must involve rapid reversible binding of EGCG to chicken liver DHFR. However, EGCG acted as a slow tight-binding inhibitor of bovine liver DHFR (Fig. 2C). In the absence of EGCG, the steady-state velocity of DHF reduction is rapidly established and only shows a minor deviation from linearity over a 15-minute period due to substrate (DHF) depletion. However, in the presence of EGCG, a time-dependent decrease in the reaction rate, which varies as a function of the inhibitor concentration, is clearly apparent in Fig. 2C and D. Further evidence for slow-binding inhibition was obtained by adding aliquots of preincubation mixtures of EGCG and the bovine liver enzyme to substrate-containing assay mixtures. Such behavior can be described by a mechanism that involves the rapid binding of the inhibitor (EGCG) to the enzyme (DHFR) to form an EI complex which then undergoes a slow isomerization to form an EI* complex (Eq. A). Such a mechanism of inhibition of DHFR has been previously reported for folate analogues such as methotrexate and deazaflavines (7, 12). A complete kinetic analysis of the inhibition of bovine liver DHFR yielded the kinetic parameters given in Table 1. Although ECG was also a potent inhibitor, polyphenols lacking the
Further evidence for EGCG binding to the same site on DHFR as methotrexate comes from the pH dependence of the $K_i^*$ for the bovine liver enzyme. A plot of $V/K_{m^{DHFR}}$ values against pH yielded a single $pK_a$ value of 8.7 ± 0.2, which is similar to that reported for the human enzyme (12). This has been interpreted in the case of the human enzyme as a shift of the $pK_a$ of Glu30 from an intrinsic value of 5.6 to an observed value of about 8.7 on DHF binding. The similarity of the two pH profiles for the bovine and human enzymes suggests that the same ionizing residue is involved in catalysis.

Because Glu30 is the only acidic residue at the pterin subsite of both enzymes (12, 14), it is considered to be the source of the proton for the reduction of DHF (12). The $p$H dependence of $K_i^*$ for EGCG binding to bovine DHFR gave a $pK_a$ value of 6.5 ± 0.12, which we assign to the Glu30 that is conserved in mammalian DHFRs. This provides further evidence for EGCG binding at the same site as DHF. A similar $pK_a$ shift was assigned to Glu30 for methotrexate binding to human DHFR (12), which is readily explained by (a) the high degree of sequence homology between the bovine and human enzymes, (b) the published structure of the human enzyme with methotrexate bound (15), and (c) our modeling of EGCG into the active site of human DHFR described below and shown in Fig. 1B.

**Molecular Modeling of the Interaction between EGCG and Dihydrofolate Reductase.** On searching the available ligand-bound human DHFR structures in the Protein Data Bank (10), we identified a 1.8-Å structure (Protein Data Bank accession code 1S3V; ref. 9) containing a tetrahydroquinazoline antifolate ligand, TQD (Fig. 1), as the best available structural match for EGCG. Using the position of TQD as a guide, EGCG was docked into this protein structure and the EGCG-protein composite was then energy minimized (Fig. 1B). Comparison with a range of other DHFR structures containing folate or various inhibitors showed that most of the EGCG lies within the consensual substrate/inhibitor envelope, with the exception of the nonester trihydroxynenzene moiety. To accommodate this ring, the Leu27 side chain is required to adopt a different orientation; a precedent for this movement is provided by the crystal structure of a Tyr27 mutant, which displays a similar geometry at this residue (16). There are specific hydrogen bonding interactions, most notably that involving Glu30. For folate and methotrexate, adjacent heterocyclic and amino nitrogens of the ligand form a pair of hydrogen bonds with the two oxygens of the Glu30 side chain (both O···N distances ≤2.8 Å). In contrast, EGCG has only a single phenolic OH group available for hydrogen bonding to Glu30 (O···O distance 2.7 Å). This is consistent with the $pK_a$ data discussed above and could explain the soft drug character of this catechin. Other EGCG-protein contacts, shown in Fig. 1B, are similar to those found for TQD.

The difference in the type of inhibition exhibited by EGCG with bovine and chicken DHFR must be due to a difference in primary sequence and hence the three-dimensional structures of these enzymes. The DHFRs from humans, cows, and chickens are quite similar, with sequence identities of 75%, 76%, and 87% for the sequence pairs human/avian, bovine/avian, and human/bovine, respectively. Structural analysis of our model showed only one residue within 4 Å of the EGCG ligand that is variable in the three sequences, namely, residue 31. This residue is located at the active site of DHFR and is Tyr in chicken, but Phe in human and bovine DHFR. Phe31 has the same side chain conformation as Tyr31 in some, but not all, of the human structures. Because this side chain has quite extensive van der Waals contacts with the EGCG ligand in our model (see Fig. 1), and interacts with folate and inhibitors such as methotrexate and trimethoprim, its mutation could have a noticeable effect on ligand binding. Indeed, the crystal structure of chicken liver DHFR complexed with NADP$^+$ and biotin showed two alternative conformations for Tyr31, and the implications of this observation in terms of the catalytic mechanism have been discussed (17).

**Inhibition of Dihydrofolate Reductase by EGCG in Cancer Cells.** To determine whether EGCG inhibits DHFR activity in vivo, a mouse lymphoma cell line (L1210) was incubated with various concentrations of EGCG in a standard folate medium. EGCG significantly inhibited L1210 growth in a concentration-dependent manner ($IC_{50} = 20$ μmol/L). If this was specifically due to inhibition of DHFR activity by EGCG, cell growth should be restored in HT

<table>
<thead>
<tr>
<th>Enzyme source</th>
<th>Inhibitor</th>
<th>$K_i$ (nmol/L)</th>
<th>$k_3$ (min$^{-1}$)</th>
<th>$k_4$ (min$^{-1}$)</th>
<th>$k_3/k_4$ (ratio)</th>
<th>$K_i^*$ (pmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bovine liver</td>
<td>EGCG</td>
<td>109</td>
<td>0.13</td>
<td>0.004</td>
<td>32.5</td>
<td>3,253</td>
</tr>
<tr>
<td></td>
<td>ECG</td>
<td>51.3</td>
<td>0.11</td>
<td>0.015</td>
<td>7.3</td>
<td>6,156</td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
<td>1.3</td>
<td>2.9</td>
<td>0.020</td>
<td>145</td>
<td>8.9</td>
</tr>
<tr>
<td></td>
<td>Trimethoprim</td>
<td>3,530</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chicken liver</td>
<td>EGCG</td>
<td>10,300</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
<td>3.6</td>
<td>6.9</td>
<td>0.026</td>
<td>265.4</td>
<td>13.5</td>
</tr>
<tr>
<td></td>
<td>Trimethoprim</td>
<td>0.49</td>
<td>2.0</td>
<td>0.086</td>
<td>23.3</td>
<td>20.2</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>Methotrexate</td>
<td>23</td>
<td>5.1</td>
<td>0.013</td>
<td>392.3</td>
<td>58.5</td>
</tr>
<tr>
<td></td>
<td>Trimethoprim</td>
<td>4.6</td>
<td>2.1</td>
<td>0.58</td>
<td>3.6</td>
<td>1,000</td>
</tr>
</tbody>
</table>

NOTE: Values for the inhibition of DHFR from different sources by methotrexate and trimethoprim were obtained from the literature (7). The values of $K_i$, $K_i^*$, $k_3$, and $k_4$ for EGCG were calculated at pH 8.02.
medium. Antifolates block the de novo biosynthesis of thymine, purines, and pyrimidines by inhibiting the synthesis of 5,6,7,8-tetrahydrofolate, an essential cofactor in these biosynthetic pathways. Cells that express hypoxanthine-guanine phosphoribosyltransferase, an enzyme essential for the recycling of purine nucleotides, can survive in the presence of antifolates in HT medium. Control experiments showed that the inhibition of growth of L1210 cells by methotrexate was greatly attenuated in HT medium (data not shown). Figure 3A shows the time-dependent inhibition of L1210 growth by 20 μmol/L EGCG. Although L1210 grown in HT medium showed a high level of inhibition reversal (Fig. 3A), complete reversal was not obtained after the second day of the experiment. Partial lifting of EGCG inhibition in HT medium is most likely due to secondary effects of EGCG at the concentration used in this assay. EGCG has been reported to have pro-oxidant activity in several cell lines (e.g., hepatoma cells; ref. 18). The production of reactive oxygen species has been associated with the inhibition of cancer cell growth by tea polyphenols (19). The inhibition of L1210 growth by EGCG was partially lifted by the inclusion of the antioxidant ascorbic acid in the reaction medium (Fig. 3A). Similar results were obtained by cotreating the cells with N-acetylcysteine (a glutathione precursor and scavenger of reactive oxygen species) or superoxide dismutase. Growing L1210 in HT medium containing ascorbic acid (Fig. 3A), N-acetylcysteine, or superoxide dismutase completely removed the inhibitory effect of EGCG. These data provide strong evidence that the major site of action of EGCG in vivo is DHFR.

Further evidence for in vivo inhibition of DHFR by EGCG is provided by experiments with lymphoma cells grown in RPMI medium with low folate levels (Fig. 3B and C). These experiments were designed to investigate whether folate depletion has an effect on the sensitivity to EGCG. Cancer cell lines in standard cell-culture medium are exposed to relatively high folate levels compared with the folate levels in human plasma (19). Consequently, the concentration of folates in the culture medium could affect the extent of EGCG inhibition of cell growth. The concentrations of EGCG needed to inhibit L1210 growth in media with low folate levels were much lower than were needed in a standard folate medium (Fig. 3B). In a low-folate medium supplemented with 30 nmol/L folic acid the IC\textsubscript{50} value decreased to 3 μmol/L, and it was then possible to study the time-dependent inhibition of L1210 growth at a lower concentration of EGCG (1 μmol/L). Under these more physiologically relevant growth conditions, inhibition by EGCG was completely reversed in HT medium. These data show that inhibition of DHFR activity could be the major mechanism of the antitumor action of EGCG at physiologic concentrations of folate substrates and blood serum levels of EGCG.

We have shown for the first time that gallated tea polyphenols act as DHFR inhibitors in vitro and in vivo, at concentrations usually found in the blood of tea drinkers. The “soft” character of such compounds could be developed for use in the prevention and treatment of cancer with significantly reduced side effects compared with those of the DHFR inhibitors currently in use in chemotherapy, such as methotrexate. An advantage of EGCG is its differential effects on normal and cancer cells. Importantly, at physiologically attainable concentrations, EGCG kills cancer cells through apoptosis, but has little or no effect on normal cells. Inhibition of DHFR by EGCG explains this differential effect because antifolate compounds are more active on cancer cells, which generally have a higher turnover of DNA. Induction of apoptosis can provide highly effective chemotherapeutic and chemopreventative strategies for cancer control. Many chemopreventative agents act through the induction of apoptosis as a mechanism for the suppression of carcinogenesis by eliminating genetically damaged cells, initiated cells, or cells that have progressed to malignancy. Thus, the soft character of EGCG together with its ability to induce apoptosis through DHFR inhibition provides a convincing explanation for the epidemiologic data on the prophylactic effects of diets high in gallated polyphenols for certain forms of cancer.

We conclude that gallated polyphenols and their derivatives have considerable potential for clinical application as anticarcinogenic agents and as antibiotics and for the treatment of psoriasis (1–3). Our data may also explain why neural tube defects such as anencephaly and spina bifida, which are usually
associated with folic acid deficiency, have been linked to high levels of maternal green tea consumption during the periconceptional period (20).

Acknowledgments
Received 9/27/2004; revised 11/18/2004; accepted 1/12/2005.

Grant support: EU INTAS Program project INTAS00-0727 (F. García-Cánovas, R.N. Thorneley, and J.N. Rodríguez-López), Fondo de Investigación Sanitaria projects 01/3025 and 02/1567 (J. Cabezas-Herrera), and Biotechnology and Biological Sciences Research Council, United Kingdom (R.N. Thorneley and M.C. Durrant). E. Navarro-Pérez has a fellowship from the Ministerio de Educación, Cultura y Deporte.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References
The Antifolate Activity of Tea Catechins

Enma Navarro-Perán, Juan Cabezas-Herrera, Francisco García-Cánovas, et al.


Updated version  Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/65/6/2059

Cited articles  This article cites 18 articles, 6 of which you can access for free at: http://cancerres.aacrjournals.org/content/65/6/2059.full.html#ref-list-1

Citing articles  This article has been cited by 14 HighWire-hosted articles. Access the articles at: /content/65/6/2059.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.